Jean Coutu Group SV was Upgraded to a Hold Rating at Desjardins

By Austin Angelo

In a new note to investors yesterday, an analyst has provided a rating update for the Services sector company, Jean Coutu Group SV (TSX: PJC.A). Keith Howlett, an analyst with Desjardins, has upgraded their rating on PJC.A to Hold , with a C$21 price target.

Howlett has an average return of 1.6% when recommending Jean Coutu Group SV.

According to TipRanks.com, Howlett is ranked #478 out of 4567 analysts.

Jean Coutu Group SV has an analyst consensus of Moderate Sell, with a price target consensus of C$20.92.

Based on Jean Coutu Group SV’s latest earnings report for the quarter ending February 28, the company posted quarterly revenue of C$789 million and quarterly net profit of C$47.8 million. In comparison, last year the company earned revenue of C$707 million and had a net profit of C$51.5 million.

The Jean Coutu Group (PJC), Inc. engages in the production and trade of pharmaceutical, health care, hygiene, and beauty products. It operates through the Franchising and Generic Drugs segments. The Franchising segment manages distribution centers and markets products under the banners of PJC Jean Coutu, PJC Clinique, PJC Jean Coutu Santé, and PJC Jean Coutu Santé Beauté. The Generic Drugs segment develops and supplies generic pharmaceuticals to wholesalers and pharmacists. The company was founded by Jean Coutu in 1969 and is headquartered in Varennes, Canada.

The company’s shares closed last Wednesday at $21.84.